The average one-year price target for Arcturus Therapeutics Holdings (NasdaqGM:ARCT) has been revised to $25.78 / share. This ...
Cathie Wood’s ARK Invest has been steadily dialing down its exposure to mega-cap tech, trimming names like Nvidia (NVDA), ...
View source version on businesswire.com: https://www.businesswire.com/news/home/20260303197744/en/ The articles, information, and content displayed on this webpage ...
Arcturus Therapeutics Public Relations & Investor Relations Neda Safarzadeh VP, Head of IR/PR/Marketing (858) 900-2682 IR@ArcturusRx.com Source: Arcturus Therapeutics Holdings Inc. The views and ...
The company expects to initiate the 12-week Phase II ARCT-032 study in the first half of 2026, enrolling up to 20 participants and focusing on safety and early signs of clinical benefit. For ARCT-810, ...
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) stock was trading lower on Wednesday after the company shared interim results from its ongoing Phase 2 trial of ARCT-032, an investigational inhaled ...
12-week safety and preliminary efficacy study in up to 20 CF participants planned to start H1 2026 Additional cost reductions planned in fourth quarter to extend cash runway Investor conference call ...
Arcturus Therapeutics Public Relations & Investor Relations Neda Safarzadeh VP, Head of IR/PR/Marketing (858) 900-2682 IR@ArcturusRx.com Source: Arcturus Therapeutics Holdings Inc. The views and ...
On January 6, Citi lowered its price target on Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) to $7 from $9 while maintaining a Neutral rating, reflecting a selective stance toward SMID-cap biotech ...
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results